Amphotericin B for Fungal Infections in Blood Cancer Patients
Treatments studied
Part of Blood & lymphatic, Infections clinical trials.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a blood cancer or blood disorder and are currently taking triazole antifungal preventive medicine
- You have a confirmed or suspected invasive fungal infection that developed while on your preventive medicine
- Your liver and kidney function are not severely damaged (specific blood test levels required)
- You are not pregnant, breastfeeding, or allergic to amphotericin B
- You are expected to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
This trial studies two types of antifungal medicines (amphotericin B and azoles) to see which works better for people with invasive fungal disease. It aims to help doctors choose the safest and most effective treatment.
This study follows children and teens with blood cancers who got a fungal infection while on preventive antifungal medicine. It looks at how well liposomal amphotericin B (AmBisome) works and how safe it is for them.
This trial studies how the body processes the antifungal drug liposomal amphotericin B (L-AmB) in patients on ECMO (a heart-lung machine). The goal is to find the right dose for treating invasive fungal infections in ICU patients who need ECMO support.
This study looks at how well a medicine called liposomal amphotericin B works for treating serious fungal infections in people who have had a solid organ transplant. It may help doctors understand the best way to use this medicine for patients like you.
Hear when a new Invasive Fungal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.